Press Enter to search · ESC to close

Crypto

Grand Pharma’s Migraine Prevention TCM Drug Doses First Patient in Phase II Trial

Grand Pharma has completed enrollment of the first patient in a domestic Phase II clinical trial of GPN01020, a Class 1.1 traditional Chinese medicine innovative drug for migraine prophylaxis. The candidate was developed from a hospital preparation and is now entering evidence-based verification after long-term clinical experience. The company called the dosing a milestone for its otorhinolaryngology TCM portfolio.

Share

Related News

新云社 share card
Long-press image above → Save to Photos / Share
Pitch us Feedback